Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pantothenate kinase 4 (inactive) is a human protein encoded by the PANK4 gene. Unlike its paralogs (PANK1–3), which possess pantothenate kinase activity and catalyze the first step in coenzyme A (CoA) biosynthesis, PANK4 is a bifunctional protein consisting of an N-terminal type II pantothenate kinase-like domain and a C-terminal phosphatase domain. However, due to specific substitutions at key catalytic residues, the human enzyme is catalytically inactive as a kinase and acts instead as a pseudoenzyme[1][3]. Its C-terminal phosphatase domain is active and acts preferentially on 4'-phosphopantetheine and oxidatively damaged forms, suggesting a role in preventing the accumulation of toxic intermediates and regulating intracellular CoA levels[2]. PANK4 is most highly expressed in muscle but is present in all tissues[2][4][5]. Disease associations include certain types of cataract[2]. Currently, there are no known clinically approved drugs targeting PANK4, and it is not considered a classic therapeutic target.
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pantothenate kinase 4 (inactive) (PANK4).